Pembrolizumab for recurrent/metastatic head and neck cancer: equally promising for Asian patients?
- PMID: 31032295
- PMCID: PMC6462627
- DOI: 10.21037/atm.2019.01.46
Pembrolizumab for recurrent/metastatic head and neck cancer: equally promising for Asian patients?
Conflict of interest statement
Conflicts of Interest: NC Schmitt has received research funding from Astex Pharmaceuticals, which is not relevant to this submission. W Ye has no conflicts of interest to declare.
Comment on
-
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.Cancer Sci. 2018 Mar;109(3):771-776. doi: 10.1111/cas.13480. Epub 2018 Feb 8. Cancer Sci. 2018. PMID: 29284202 Free PMC article. Clinical Trial.
References
-
- Fitzmaurice C, Allen C, Barber RM, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2017;3:524-48. 10.1001/jamaoncol.2016.5688 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources